Tag: Advanced Accelerator Applications

2021 Monica Warner Award: Call for Nominations

Advanced Accelerator Applications (AAA), a Novartis company, has announced that nominations are open for the 12th Annual Monica Warner Award!  AAA is continuing the Novartis tradition of sponsoring the award, which commemorates the life and work …

News and Notes from the Carcinoid Cancer Foundation, October 2021

Congratulations to NET expert Pamela Kunz, MD, who was named Woman Oncologist of the Year! Dr. Kunz is Associate Professor of Medicine (Medical Oncology), Director of the Center for Gastrointestinal…

Lisa Yen Selected as 2020 Monica Warner Award Recipient

Congratulations to Lisa Yen, NP, NBC-HWC, of LACNETS upon being selected as the 2020 Monica Warner Award recipient! The award, established by Novartis Oncology in 2009, is presented annually to “honor a patient, supporter, or caregiver who most embodies…

2020 Monica Warner Award: Call for Nominations

Advanced Accelerator Applications (AAA), a Novartis company, has announced that nominations are open for the 11th Annual Monica Warner Award!  AAA is continuing the Novartis tradition of sponsoring the award, which commemorates the life and work of…

FDA Approves LUTATHERA® for Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors

BREAKING NEWS: On January 26, 2018 the US Food and Drug Administration approved LUTATHERA® marking the first time a radioactive drug, or radiopharmaceutical, has been approved for the treatment of gastroenteropancreatic neuroendocrine tumors …

NET Community Bicycle Raffle Recipients

In conjunction with Worldwide NET Cancer Awareness Day, November 10, the Carcinoid Cancer Foundation and Advanced Accelerator Applications are very excited to announce recipients of the recent Bicycle Giveaway Raffle.

Stefano Buono, CEO of Advanced…

Gallium 68 PET/CT Scanning for Neuroendocrine Tumors — Information and Locations (updated January 26, 2019)

The US Food and Drug Administration’s (FDA) June 1, 2016 approval of the Gallium-68 PET/CT DOTATATE scan using NETSPOT® heralded a new age of nuclear imaging for neuroendocrine tumors in the United States.

Fighting NET Cancer with Grace and Gratitude

The Carcinoid Cancer Foundation is very excited to share what we have planned around this year’s Worldwide NET Cancer Awareness Day, November 10, and hope you will help us spread the word about NET cancer to support and inspire one another, and those yet…

October Luncheon with the Experts in New York City for the Carcinoid and Neuroendocrine Tumor Community

Join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for Luncheon with the Experts in New York City on Sunday, October 16, 2016.  This special program was initiated and is sponsored by the Big Apple NETs support group,…

One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers

The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration last week, a decision from the FDA is expected by early 2017.  Additionally, an Expanded…